儿童分化型甲状腺癌幸存者接受放射性碘治疗对女性生育力的长期影响
本研究纳入56例儿童期分化型甲状腺癌女性幸存者,评估其生育特征及抗苗勒管激素(AMH)水平。中位随访15.4年,中位累积131I剂量7.4 GBq。结果显示幸存者AMH水平与420名未患癌女性对照无显著差异(2.0 μg/L vs 1.6 μg/L,p=0.244),且未报告早绝经,提示儿童期131I治疗对女性生育力未见重大异常。
要点
- 儿童期DTC幸存者中位随访15.4年,未报告早绝经。
- 幸存者与对照的AMH中位水平无显著差异(2.0 vs 1.6 μg/L,p=0.244)。
- 131I累积剂量与AMH水平无显著关联(rs=0.210,p=0.130)。
核心结论
- 儿童期接受131I治疗的分化型甲状腺癌女性幸存者,其生育特征及卵巢衰竭预测指标未见重大异常。
研究设计与样本
- 纳入1970年至2013年间诊断年龄≤18岁的儿童分化型甲状腺癌女性幸存者,排除随访不足5年或诊断前后发生其他恶性肿瘤者。
- 幸存者填写生育特征问卷(初潮年龄、绝经、妊娠、妊娠结局、辅助生殖治疗需求),评估时年龄<18岁者使用不含妊娠问题的问卷,并结合病历资料。
- 测定血清AMH水平,与420名未接受癌症治疗的女性对照比较。
主要发现
- 共评估56例幸存者,中位年龄31.0岁(IQR 25.1-39.6),中位随访15.4年(IQR 8.3-24.7)。
- 中位累积131I剂量为7.4 GBq/200.0 mCi(IQR 3.7-13.0 GBq/100.0-350.0 mCi)。
- 评估时年龄≥18岁的55例幸存者中,25例报告64次妊娠,其中45次活产;10.9%曾就诊生育门诊;无幸存者报告早绝经。
- 幸存者与对照组的AMH评估年龄无显著差异(p=0.268);AMH中位水平无显著差异[2.0(IQR 1.0-3.7)μg/L vs 1.6(IQR 0.6-3.1)μg/L,p=0.244]。
- 幸存者中131I累积剂量与AMH水平无显著关联(rs=0.210,p=0.130)。
临床怎么用
- 原文结论认为儿童期接受131I治疗的女性DTC幸存者未见生育特征及卵巢衰竭预测指标的重大异常,未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Differentiated thyroid carcinoma (DTC) during childhood is a rare disease. Its excellent survival rate requires a focus on possible long-term adverse effects. This study aimed to evaluate fertility in female survivors of childhood DTC by assessing various reproductive characteristics combined with anti-Müllerian hormone (AMH) levels (a marker of ovarian reserve). Methods: Female survivors of childhood DTC, diagnosed at ≤18 years of age between 1970 and 2013, were included. Survivors were excluded when follow-up time was less than five years or if they developed other malignancies before or after diagnosis of DTC. Survivors filled out a questionnaire regarding reproductive characteristics (e.g., age at menarche and menopause, pregnancies, pregnancy outcomes, need for assisted reproductive therapy). Survivors aged <18 years during evaluation received an altered questionnaire without questions regarding pregnancy and pregnancy outcomes. These data were combined with information from medical records. AMH levels were measured in serum samples and were compared with AMH levels from 420 women not treated for cancer. Results: Fifty-six survivors with a median age of 31.0 (interquartile range, IQR, 25.1-39.6) years were evaluated after a median follow-up of 15.4 (IQR 8.3-24.7) years. The median cumulative dose of 131I administered was 7.4 (IQR 3.7-13.0) GBq/200.0 (IQR 100.0-350.0) mCi. Twenty-five of the 55 survivors aged 18 years or older during evaluation reported 64 pregnancies, 45 of which resulted in live birth. Of these 55, 10.9% visited a fertility clinic. None of the survivors reported premature menopause. Age at AMH evaluation did not differ between DTC survivors and the comparison group (p = 0.268). Median AMH levels did not differ between DTC survivors and the comparison group [2.0 (IQR 1.0-3.7) μg/L vs. 1.6 (IQR 0.6-3.1) μg/L, respectively, p = 0.244]. The cumulative dose of 131I was not associated with AMH levels in DTC survivors (rs = 0.210, p = 0.130). Conclusions: Female survivors of DTC who received 131I treatment during childhood do not appear to have major abnormalities in reproductive characteristics nor in predictors of ovarian failure.
引用
- Nies M, Cantineau AEP, Arts EGJM, et al. Long-Term Effects of Radioiodine Treatment on Female Fertility in Survivors of Childhood Differentiated Thyroid Carcinoma. Thyroid. 2020. PMID: 32079487. doi:10.1089/thy.2019.0560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。